The scientist’s investigation covers issues in Internal medicine, Oncology, Ovarian cancer, Surgery and Gynecologic oncology. His Internal medicine study is mostly concerned with Bevacizumab, Chemotherapy, Clinical trial, Randomized controlled trial and Hazard ratio. His studies deal with areas such as Cancer and Urology as well as Chemotherapy.
His Oncology study incorporates themes from Placebo, Clinical endpoint, Gynecology, Carcinoma and Stage. Bradley J. Monk has researched Ovarian cancer in several fields, including Malignancy, Progression-free survival, Gene expression, Bioinformatics and Breast cancer. His Surgery research incorporates themes from Tolerability and Drug development.
His scientific interests lie mostly in Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Gynecologic oncology. His research on Internal medicine often connects related areas such as Surgery. His Oncology research is multidisciplinary, relying on both Advanced ovarian cancer, Clinical endpoint, Recurrent Ovarian Cancer and Trabectedin.
His Ovarian cancer study also includes fields such as
Bradley J. Monk spends much of his time researching Internal medicine, Oncology, Ovarian cancer, Chemotherapy and In patient. His work is connected to Bevacizumab, Clinical endpoint, Adverse effect, Newly diagnosed and Cervical cancer, as a part of Internal medicine. His Bevacizumab research includes elements of Pembrolizumab, Gynecologic oncology and Paclitaxel.
His Oncology study combines topics from a wide range of disciplines, such as Trabectedin, Poly ADP ribose polymerase, Advanced ovarian cancer, Biomarker and Recurrent Ovarian Cancer. While the research belongs to areas of Ovarian cancer, he spends his time largely on the problem of Clinical trial, intersecting his research to questions surrounding Cancer research. His Chemotherapy research is multidisciplinary, incorporating elements of Debulking, Interim analysis, Serous fluid and Toxicity.
Bradley J. Monk mainly focuses on Internal medicine, Oncology, Ovarian cancer, Cancer and Clinical endpoint. In general Internal medicine, his work in Phases of clinical research, Cervical cancer, Chemotherapy and Newly diagnosed is often linked to In patient linking many areas of study. His work deals with themes such as Metastatic cervical cancer, Adverse effect, Bevacizumab, Recurrent disease and Recurrent Ovarian Cancer, which intersect with Oncology.
In his study, Mesothelin, Immunohistochemistry, Tolerability and Monoclonal antibody is strongly linked to Biomarker, which falls under the umbrella field of Ovarian cancer. His work in Cancer covers topics such as Intensive care medicine which are related to areas like Targeted therapy and Health professionals. The study incorporates disciplines such as Carboplatin, Placebo and Randomization in addition to Clinical endpoint.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari;Michael W. Sill;Harry J. Long;Richard T. Penson.
The New England Journal of Medicine (2014)
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Robert A. Burger;Michael W. Sill;Bradley J. Monk;Benjamin E. Greer.
Journal of Clinical Oncology (2007)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René DePont Christensen.
The New England Journal of Medicine (2019)
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
John B. Welsh;Patrick P. Zarrinkar;Lisa M. Sapinoso;Suzanne G. Kern.
Proceedings of the National Academy of Sciences of the United States of America (2001)
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
Bradley J. Monk;Michael W. Sill;D. Scott McMeekin;David E. Cohn.
Journal of Clinical Oncology (2009)
Carcinogenic human papillomavirus infection.
Mark Schiffman;John Doorbar;Nicolas Wentzensen;Silvia de Sanjosé.
Nature Reviews Disease Primers (2016)
Latest research and treatment of advanced-stage epithelial ovarian cancer
Robert L. Coleman;Bradley J. Monk;Anil K. Sood;Thomas J. Herzog.
Nature Reviews Clinical Oncology (2013)
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A. Burger;Mark F. Brady;Michael A. Bookman;Gini F. Fleming.
Obstetrical & Gynecological Survey (2012)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner.
Journal of Clinical Oncology (2010)
Adhesions after extensive gynecologic surgery: Clinical significance, etiology, and prevention * ** *
Bradley J. Monk;Michael L. Berman;F.J. Montz.
American Journal of Obstetrics and Gynecology (1994)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: